Alise Reicin - 31 Dec 2025 Form 4 Insider Report for Tectonic Therapeutic, Inc. (TECX)

Role: Chief Executive Officer, Director
Signature: /s/ Daniel Lochner, Attorney-in-Fact
Issuer symbol: TECX
Transactions as of: 31 Dec 2025
Net transactions value: +$26,099
Form type: 4
Filing time: 05 Jan 2026, 17:02:32 UTC
Previous filing: 29 Sep 2025
Next filing: 10 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
REICIN ALISE	Chief Executive Officer, Director	C/O TECTONIC THERAPEUTIC, INC., 490 ARSENAL WAY, SUITE 210, WATERTOWN	/s/ Daniel Lochner, Attorney-in-Fact	05 Jan 2026	0001757533

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TECX	Common Stock	Options Exercise	$26,099	+10,966	+4.8%	$2.38	239,151	31 Dec 2025	Direct
holding	TECX	Common Stock						124,530	31 Dec 2025	By Trust	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TECX	Employee Stock Option (Right to Buy)	Options Exercise		-10,966	-32%		22,957	31 Dec 2025	Common Stock	10,966	$2.38	Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares are held by the Reicin-Boiarsky Family Trust (the "Trust"). The Reporting Person's spouse is a co-trustee of the Trust. Accordingly, the Reporting Person may be deemed to have shared voting and dispositive power over the securities held by the Trust. The Reporting Person disclaims beneficial ownership of the shares held by the Trust except to the extent of her pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F2	The shares subject to the option vested as follows: (i) 4,079 shares on June 30, 2024; (ii) 4,078 shares on July 31, 2024, (iii) 4,078 shares on August 31, 2024, (iv) 4,079 shares on September 30, 2024, (v) 4,078 shares on October 31, 2024, (vi) 1,297 shares on November 30, 2024, (vii) 4,078 shares on January 31, 2025, (viii) 4,078 shares on February 28, 2025 and (iv) 4,078 shares on March 31, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date..
F3	Received in exchange for a stock option to acquire 63,478 shares of common stock pursuant to that certain merger, as more fully described on the Reporting Person's Form 4 filed with the Securities and Exchange Commission on June 24, 2024. https://www.sec.gov/Archives/edgar/data/1681087/000141588924017952/xslF345X05/form4-06242024_080648.xml